IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31

Disc Medicine, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$78.93+22.09 (+38.86%)

Close on Oct 19, 2026

Market cap: $3.05B
P/E (TTM): –
Dividend yield: –

Disc Medicine, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	171	97	69	33	25	28
Selling, General & Admin	65	33	22	–	–	–
General & Administrative	–	–	22	14	5.76	5.87
Operating Expenses	236	130	91	47	31	34
Operating Income	-236	-130	-91	-47	-31	-34
Interest Expense	3.61	0.57	0	–	2.16	6.83
Interest & Investment Income	28	21	15	0.71	0.01	0.04
Other Non-Operating Income	24	21	15	0.65	-5.04	–
Merger & Restructuring Charges	–	–	–	–	1.40	–
Asset Impairment Charges	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	–	0.30	–
Pretax Income	-212	-109	-76	-47	–	–
Income Tax Expense	0.36	0.36	0.10	0	–	–
Net Income incl. Noncontrolling Interests	–	–	-76	-47	-36	-41
Net Income	-212	-109	-76	-47	-36	-41
Preferred Dividends	–	–	–	–	0	–
Net Income to Common	–	–	-76	-47	-36	–
EPS (Basic)(per share)	-6.01	-3.96	-3.42	-45.05	-40.95	-2.70
EPS (Diluted)(per share)	-6.01	-3.96	-3.42	-45.05	-40.95	-2.70
Shares Outstanding (Basic, Weighted)(shares)	35	28	22	1.04	0.88	15
Shares Outstanding (Diluted, Weighted)(shares)	35	28	22	1.04	0.88	15
EBITDA	-236	-130	-91	-47	-31	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -35.9%

Financial strength

Current ratio: 24.14
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 325.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.74
Dividend yield: –